



Translational Research

Alcohol • Drugs • Toxicology

Annual Report

2022

Edith Collins Centre - Annual Report 2022

The Edith Collins Centre (ECC) is a Translational Research in Alcohol Drugs and Toxicology, established to increase clinical research capacity in the alcohol, drugs and toxicology fields as a partnership between Sydney Local Health District and the University of Sydney.

Our multi-disciplinary research ranges from early interventions for drug and alcohol use, genetic and molecular mechanisms of tissue injury, clinical trials in the treatment of substance use disorders, and encompasses a broad range of disciplines including clinical toxicology, addiction medicine, public health, epidemiology, hepatology, mental health and Aboriginal and Torres Strait Islander health. The Centre comprises several highly successful research groups conducting nationally and internationally leading work in these areas, achieving world-first outcomes in their fields, including the establishment of notable international collaborations and consortia and large multi-national cohorts. The work is mainly supported by external peer-reviewed grants. ECC Staff Specialists also provide leadership and teaching in the Speciality of Addiction Medicine at the University of Sydney.

Specifically, our research is aligned across the following five key areas of research:

- Clinical Toxicology and Pharmacology (Prof Andrew Dawson, Prof Nick Buckley, A/Prof Darren Roberts)
- Aboriginal peoples and other priority populations Substance Use (Prof Kate Conigrave, A/Prof Kylie Lee, Dr Michael Doyle)
- Alcohol Biology, and Genetics of Liver Disease (Clinical Prof Devanshi Seth, Prof Paul Haber)
- Clinical Research in Alcohol, Addictive Behaviours & Treatment (Prof Kirsten Morley, Prof Paul Haber, Prof Andrew Baillie, Dr Warren Logge)
- Illicit Drug Use (Prof Carolyn Day)

Clinical Toxicology includes acute and chronic medicine and chemical poisoning, serious adverse prescribed and non-prescribed drug reactions, and toxicology that contributed to a substantial source of morbidity and mortality across the world. The team (led by Professors Andrew Dawson and Nick Buckley) has established large prospective cohorts of acute poisoning and developed treatment guidelines resulting in national and international policy and regulatory changes. Much of their national research is based on detecting early signals of significant drug toxicity and measuring the public health impact of regulatory change. This group has led the development of the NSW Poisons Information Centre research program and used data to describe many developing trends in poisoning including pharmaceuticals and drug use. The team has been funded by NHMRC Program and CRE Grants (CRE in Medicines Intelligence, and CRE in Translational Venom and Antivenom Research) along with Project grants and other forms of support. Recent projects include:

- The Australian Toxicology Monitoring (ATOM) and Australian Snakebite Projects (ASP), which identify the clinical effect and response to treatment from various poisonings and snakebites.
- An evaluation of the patterns of use and poisoning with various substances like codeine, paracetamol, pregabalin, etc.
- A randomised stepped wedge trial of scaling up of a community-based alcohol education program in rural Sri Lankan villages, and its effects on alcohol use, associated harms, depression and social capital.
- A comparative study of oral and intravenous antidotes for acute paracetamol poisoning
- Long-term effects on kidney function and health after severe acute pesticide poisoning and snake envenomation.

Aboriginal peoples and other priority populations: (led by Dr Michael Doyle and Associate Professor Kylie Lee) involves developing culturally appropriate, accessible and innovative approaches to prevent or treat alcohol or other drug use disorders among Aboriginal and Torres Strait Islander peoples (hereafter referred to as Aboriginal Australians). The ongoing impacts of colonisation as well as the unique cultural strengths of Aboriginal Australians, requires a specific focus. This research group also studies prevention and treatment need in other priority populations, including pregnant women, and in specific cultural or religious settings, including in Muslim majority populations.

Founded on longstanding partnerships with these communities across Australia, focus is on culturally appropriate and practical work. Current research includes:

- A Centre for Research Excellence (CRE): Indigenous Health and Alcohol: funded by NHMRC to recruit and support Aboriginal Australian researchers. The CRE draws on the wide range of skills among its Aboriginal researchers (including trainees, early career researchers, collaborators) plus the broader investigator team. The Centre combines cultural, community, health service, research and policy expertise. The CRE has mentored a range of Aboriginal researchers, including 9 post-graduate research students, 3 early career researchers, and 3 trainees.
- Studies of the treatment and prevention needs of Aboriginal and non-Aboriginal people in prisons. This includes examining if there are ways to better address unmet needs.
- Studies of an iPad App that provides an acceptable and valid, but user-friendly way to help Aboriginal and Torres Strait Islander peoples to self-report their drinking. With voiceover in one traditional language (Pitjantjara) it has been shown to work across language and cultural differences. The App provides immediate tailored feedback on drinking. This App is now also being used among pregnant women.
- A cluster randomised trial examining a model of support for 22 Aboriginal and Torres Strait Islander community controlled primary care services around alcohol care.
- The group contributes to projects across other cultural settings, including in Muslim Majority countries, in Sri Lanka and in Thailand.

Clinical Research in Alcohol & Addictive behaviours and Treatment is a major area of interest with ongoing randomised control trials, including comorbid substance abuse and suicide risk. The team (led by Professor Kirsten Morley) is leading world first research into alcohol dependence, alcoholic liver disease and their associated psychological comorbidities. The team is currently conducting a number of randomised clinical trials testing novel treatments for alcohol addiction, and how to optimise the response to treatment and improve translation of evidence-based approaches into practice. These include:

Discovery

- A study of cannabidiol (CBD) examining the effect of CBD on a range of different functions such as functional connectivity between brain regions, brain activity in response to alcohol and anxiety cues, brain metabolite levels in addition to measures of craving, sleep and mood.
- An MRI study comparing the action of topiramate and naltrexone on functional connectivity between brain regions, brain activity in response to alcohol and anxiety cues, brain metabolite levels and the role of genotypes in these actions.
- A predictive MRI study examining neural, cognitive and epigenetic predictors of response to MDMA assisted exposure therapy to treat comorbid PTSD and AUD.

Treatment

- A randomised, double blind, controlled trial comparing naltrexone to topiramate in the treatment of alcohol dependence. It comprises of a 12-week treatment program with study medications (naltrexone or topiramate) and medical management. NHMRC funded. (2019-2021)
- A randomised, double blind, controlled trial investigating whether N-acetylcysteine is a safe and effective treatment for reducing heavy alcohol consumption. In this study participants are randomly allocated to N-acetylcysteine or matched placebo and undergo a 12-week treatment program with study medications (NAC or placebo) and medical management.

Translation

- National clinical guidelines for treatment of Alcohol problems. The ECC team led a national working group to revise and update these guidelines and generate implementation tools. (2018-2021)
- An evaluation of the effectiveness of the Pathways to Comorbidity Care (PCC) training program in improving the management of comorbid substance use and mental disorders using an integrated comorbidity management approach. Both the clinical practice outcomes and the implementation outcomes were evaluated. Funded by the NSW Health Translational Research Grant Scheme. (2017-2020)
- Following on from the PCC project, a needs assessment of drug and alcohol and mental health nurses is being conducted to inform a process of engaging leadership in implementing an integrated care management approach to comorbid drug and alcohol and mental disorders with nurses. (2021-2023)

Alcohol biology, treatment and genetics of liver disease is an important area of research at DHS within the Alcoholic Liver Disease Research Program (led by Clinical Professor Devanshi Seth). The team focuses on clinical and basic research in liver disease to understand the mechanisms of how alcohol injures the liver and identify potential genetic and non-genetic biomarkers as therapeutic and/or diagnostic agents. The team is investigating the cellular and molecular mechanisms of liver cirrhosis and compensatory liver regeneration in clinical specimens and in experimental models of alcohol-induced liver injury.

The multinational GenomALC Consortium, founded and led by Dr Seth, comprises more than forty investigators across multiple sites in seven countries. GenomALC is at the international forefront in the field of genetics/genomics of alcohol-related liver cirrhosis/disease. GenomALC has continuously been funded Category 1 National Institute on Alcohol Abuse and Alcoholism grants since 2011 by the prestigious National Institutes of Health (NIH), USA. The group has established the world's largest database and biobank of >6700 alcohol drinkers with a linked clinical database critical to study the genetics of liver disease and alcohol use disorders, and identified novel genetic factors that increase risk of cirrhosis (Hepatology 2021; Am J Gastroenterol 2020). Development of a novel Genetic Risk Score for risk stratification in drinkers (J Hepatology 2022) underpinning the novel concept and implementation of this research is on way to translation. This has the potential to significantly impact the field of genomics and personalised medicine for patients.

Animal genetic (zebrafish) models of alcohol- and high fat-induced fatty liver disease have been created by the group that show increased triglyceride accumulation in the liver with reduced b-oxidation and increased lipid synthesis pathways on exposure to alcohol/HFD, suggesting a double whammy for development of fatty liver. These exciting findings in our models help ongoing studies to

understand the genetic basis of lipotoxicity in liver diseases. Prof Seth has formed new collaborations with industry partner Ionised Technologies Pty Ltd (Sydney) and USYD Biomedical Engineering developing nanoparticle drug delivery systems to target liver lipid.

Seth's group in collaboration with the Clinical Pathology Department, RPAH, also established biochemical tests for alcohol metabolite Peth as a direct biomarker of alcohol consumption. Peth is now approved by NSW Health Pathology and is currently offered at RPAH as routine blood test for clinical use by liver and alcohol clinics Australia wide.

Illicit Drug use team (led by Professor Carolyn Day) examines substance use and related harms in vulnerable populations. In particular, it evaluates the influences and improvements to service use and delivery in this area. The program has close connections with the Sydney Women's and Drug Research group (SWaDR) as well as NGOs including Uniting Sydney Medically Supervised Injecting Centre and the NSW Alcohol and Drug Foundation. Recent projects include:

- Alcohol and other Drugs Outcomes Register (AoDOR): Health Systems Access and Patient Journey
- Validation and international comparison of the street value of prescription and illicit drugs using Street Rx data.
- Examining COVID-19 related changes to delivery of opioid agonist treatment
- Development of a model of care for substance use in pregnancy and parenting for Sydney Local Health District.
- Understanding driving-related safety for individuals who receive opioid agonist treatment (OAT).
- The ADM users into treatment (ADMiT) study: linking people who use automatic dispensing machines with the hepatitis c cascade of care.
- Characteristics and needs of women seeking treatment for substance use disorders in NSW.
- Understanding the factors facilitating or hindering utilisation of drug and alcohol services for the Muslim and Arabic speaking community in Sydney
- Suicide prevention project at Uniting Medically Supervised Injecting Centre (Uniting MSIC)
- Evaluation of drug and alcohol services for young people in Sydney including client and practitioner perspectives, cultural competency and the role of agency and aspiration in youth treatment

Other Research Collaborations, Medication Education and Training

DHS Research has a number of Translational Research projects that aim to increase uptake of evidence-based treatment. These projects are funded by NHMRC and NSW Health and include: increasing uptake of evidence-based treatment for alcohol problems in Australia's First Peoples, improving the management of comorbid mental health and substance use with an integrated approach (including a multi-modal training package to several sites across NSW Health LHD's) and a shared care pathway for the treatment of alcohol use disorders in primary care.

DHS is also an active member of the NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), which is a collaborative network of NSW Local Health District and Health Network services engaged in clinical research in the alcohol and other drug (AOD) sector. In 2022, DHS Research unit as part of the Edith Collins Centre contributed to 94 peer-reviewed journal publications, 1 book and 2 book chapters/monographs, 34 national and international conference presentations including media appearances, and 47 active grants amounted to over \$70 million.

DHS boast a large number of collaborations with external groups: Clinical Services of SLHD (Gastroenterology/Liver Services, Emergency Department, Nursing, Pharmacy, Women and Babies

Services, Women Children and their Families Institute, Pain Management Services at RPAH and Concord Hospitals, Mental Health Services, Public Health, Community Health, Oral Health and Aged Care, Aboriginal Health), HIV and Related Programs (HARP), Health promotion, Other Local Health Districts (South Eastern Sydney LHD, Hunter New England LHD, Northern Sydney LHD and South West Sydney LHD), The University of Sydney Matilda Centre, Brain and Mind Centre, United Medically Supervised Injecting Centre, NSW Poisons Information Centre, National Drug and Alcohol Research Centre (NDARC), Centenary Institute of Cancer Medicine and Cell Biology and South Asian Clinical Toxicology Research Collaboration (SACTRC), Burnett Institute, Melbourne, NSW Alcohol and Drug Foundation, Network of Alcohol and other Drug Agencies (NADA), Redfern Legal Centre, Youth INsearch, Blackdog Institute, NSW Users and AIDS Association (NUAA), the Aboriginal Drug and Alcohol Council, South Australia, and the School of Medicine, Kufa University, Iraq.

Medical Education is a key focus of the Research Unit. The fields of substance use, and related health and social consequences are major topics for undergraduate programs in Medicine and the Health Sciences due to the high prevalence of these issues and their major impact. Our staff are currently teaching in Addiction within the University's Faculty of Medicine and Health, across Dentistry, and Pharmacy and Public Health and the brain and mind sciences. Prof Day has coordinated addiction medicine education in the Sydney Medical Program since 2007.

All groups are involved in continuously training and teaching medical and science graduates (Honours, Masters, MPhil and PhD) and students in Aboriginal health promotion (GradDiplIndigHP). Group members are engaged in the placement of overseas trainees/students, teaching/training of GPs and Aboriginal drug and alcohol workers and other clinicians across Australia. We have developed a Masters in Clinical Toxicology distance learning course and Open-source curriculum, Master of Public Health unit of study "Alcohol, Drugs and Health" and the Addiction unit of study in the Brain and Mind Centre (BMC) post-graduate program. There are opportunities to undertake postgraduate studies in the above areas, from basic science, clinical or public health perspectives.

Key 2022 achievements

New grants awarded 2022 (Total new funding commencing in 2023 = \$ 20,305,962)

- 2024-2028- Medical Research Future Fund (MRFF) Primary Health Care Digital Innovations-Making it easier for Aboriginal and Torres Strait Islander primary health care services to screen for risky drinking and provide tailored feedback: adapting the Grog Survey App. \$3,466,749. Lee K, Conigrave J, Wilson S, Hayman N, Conigrave K, Percival N, Chikritzhs T, Dawson A, Tracy M, Morley K, Doyle M, Fitts M, Weatherall T
- 2023-2028 Research and Innovation for Global Health Transformation (RIGHT) Programme: NIHR203140 -Preventing Deaths from Acute Poisoning in Low- and Middle-Income Countries. UK£4,985,473 (~ \$ 9,219,076). Eddleston M, Gawarammana I, Wickramasuriya S, Street A, Dear J, Hassanian-Moghaddam H, McDonald R, Hovda KE, Buckley N, Konradsen F, Sandilands E, Karunarathne A, Weir C, Tse ML, Bhalla A, Marks C, Ghose A.
- 2022-2027 – NSW Health PRSP - Prevention Research Program. \$500,000. Haber P, Doyle M, Day C, Lee K, Morley K, Buckley NA.
- 2023-2027 - NHMRC Synergy Grant- Improving Aboriginal health by understanding the influence of early life environments and contacts with health and social service systems over time and across generations. \$ 5,000,000. Mitrou F, Zubrick S, Milroy H, Coffin J, Hamilton S, Brennan-Jones, C, Schurer S, Davis E, Richmond P, Passmore H. (Conigrave K is an Associate investigator)
- 2022-2026 NHMRC CTC 2014980. A randomised controlled trial of cannabidiol (CBD) in the treatment of cannabis dependence \$2,120,137.80. Lintzeris N, Lubman D, Doyle M, Dunlop A, Mills J, Harrod M, Arunogiri S, Malouf, Haber P, Freeman A.

Awards

- Kylie Lee, recipient of the Australasian Professional Society on Alcohol and other Drugs (APSAD) *Mentor Award 2022*. The Mentor Award is granted to an individual who has made a notable impact on the career development of clinicians, researchers, or students through mentoring and support.
- Kate Conigrave, selected to present the prestigious annual James Rankin Oration at the 2022 APSAD conference.
- Centenary Award 2022 Q1 \$5000: Publication in high impact factor journal as senior author (Whitfield JW...D Seth, J Hepatol 2022)
- Centenary Travel Award support of \$3,000 for ALD group to attend international conference (D Seth, Apr 2022)
- Tessa Hitchins - Honours (University of Sydney – 1st Class awarded 2022) – researching deaths following poisoning.

Academic staff (n=29)

- Professor Andrew Baillie, Professor, Allied Health (USYD); Clinical Psychologist (SLHD)
- Professor Nicholas Buckley, Professor, Clinical Pharmacology (USYD); Clinical Toxicologist
- Professor Kate Conigrave, Senior Staff Specialist (SLHD); Joint Director, Centre of Research Excellence in Indigenous Health and Alcohol (USYD); Conjoint Professor, Addiction Medicine (USYD)
- Professor Paul Haber, Clinical Director, Drug Health Services (SLHD); Head, Speciality of Addiction Medicine (USYD)
- Professor Kirsten Morley, Specialty of Addiction Medicine (USYD)
- Professor Carolyn Day, Research Education Academic Director, Faculty of Medicine and Health (USYD)
- Dr James Conigrave, Research Fellow, Speciality of Addiction Medicine (USYD)
- Professor Andrew Dawson, Senior Staff Specialist (SLHD); Clinical Professor, Pharmacology and Toxicology (USYD)
- Dr Rose Cairns, Senior Lecturer and NHMRC Emerging Leadership Fellow (USYD)
- Dr Kate Chitty, Research Fellow, USYD
- Dr Michael Doyle, Senior Research Fellow, Centre of Research Excellence in Indigenous Health and Alcohol (USYD)
- Dr Mohamed Fahim, A/Research Manager, Senior Research Fellow (USYD)
- Dr Cathy Heyes
- Dr Nazila Jamshidi, Staff Specialist (SLHD); Clinical Senior Lecturer, Central and Western Clinical Schools
- Associate Professor Kylie Lee; Deputy Director, Centre of Research Excellence in Indigenous Health and Alcohol (USYD); Visiting Fellow Centre for Alcohol Policy Research (LTU); Adjunct Associate Professor, National Drug Research Institute (Curtin University); Visiting Fellow, Burnet Institute
- Dr Warren Logge, Post-doctoral Research Officer
- Dr Maja Moensted, Lecturer, Post-doctoral Research Officer (USYD)
- Dr Lauren Monds, Senior Lecturer, Specialty of Addiction Medicine (USYD)
- Dr Firouzeh Noghrecchi, Statistician (USYD)
- Dr Jacques Raubenheimer, Statistician (USYD)
- Dr Sharon Reid, Career Medical Officer (SLHD); Senior Lecturer, Specialty of Addiction Medicine and School of Public Health (USYD)
- Dr Ben Riordan, Post-doctoral Research Officer

- Dr Amanda Roxburgh, Post-doctoral Research Associate
- Associate Professor Darren Roberts, Staff Specialist (SLHD)
- Clinical Associate Professor Devanshi Seth, Principal Scientist (SLHD); Head, Alcoholic Liver Disease Laboratory (Centenary Institute); Specialty of Addiction Medicine and Specialty of Clinical Medicine (USYD)
- Dr Bethany White, Clinical lecturer
- Adjunct Associate Professor Scott Wilson, Joint-Director, Centre of Research Excellence in Indigenous Health and Alcohol (USYD)
- Dr Danni Zheng, Statistician/Epidemiologist
- Dr Eva Louie, Research Assistant

Professional staff/affiliates (n=31)

- Claire Adams, Research Assistant
- Zein Albedeen Ali, Research Assistant
- Susan Anderson, Clinical Research Nurse
- Farah Al Ansari, Research Assistant
- Mustafa Al Ansari, Research Assistant
- Annabelle Chidiac, Research Assistant
- Dr Heidi Coupland, Post-doctoral Research Officer
- Bebe DeSouza, Research Assistant
- Monika Dzidowska, Research Program Manager
- Brennan Geiger, Research Assistant
- Dr Vicki Giannopoulos, Research Officer
- Tristan Hurzeler, Research Assistant
- Sophia Little, Research Officer
- Summer Loggins, Research Administrative Assistant
- Linda Mirabilio
- Dr Janaka Pushpakumara, Research Officer, Psychologist
- Taleah Reynolds, Administration and Research Support
- Natalia Uthurralt, Research Assistant
- Dr Chris Tremonti, Advanced Trainee
- Dr Anastasia Volovets, Staff Specialist in Gastroenterology and Hepatology, Addiction Medicine and Toxicology
- Daniel Winter, Research Officer
- Dr Marguerite Tracy
- Dr Catherine Zheng, Research Assistant
- Ms Grace Balicki – Senior clinical trials coordinator
- Mr Lachlan Oldfield – Clinical research associate
- Mr Miro Sounders – Research assistant
- Ms Kristiane Pacou Dunbar – Research assistant
- Ms Ellen Towers – Research assistant
- Ms Caoline Dale – Clinical psychologist
- Mr Joel Hoffman – Clinical psychologist
- Ms Victoria Chappel – Clinical psychologist

Higher Degree Students (PhD and MPhil) (n=23)

- Tristan Hurzeler, PhD student
- Winston Kardell, PhD student

- So Bi Kim, PhD student
- Jessy Lim, PhD student
- Sophia Little, PhD student
- Ali Makki, PhD student
- Rhys Mantell, PhD student
- Erica Martin, PhD student
- Tammy Merrick, PhD student
- Van Long Nguyen, PhD student
- Dr Varan Perananthan, PhD student
- Gemma Purcell-Khodr, PhD student
- Annalee Stearne, PhD student
- Dr Natalie Thurtle, PhD student
- Christopher Tremonti, PhD student
- Teagan Weatherall, PhD student
- Susan Welch, PhD student
- Daniel Winter, PhD student
- Amelia Woods, PhD student
- Ramya Padmavathy Radha Krishnan
- Kristiane Pacou Dunbar, Phd Student
- Ellen Towers, PhD student
- Josh Watt, PhD student

Masters/Other Post Graduate Students (n=15)

- Rachel Braude, Doctor of Medicine
- Lynette Bullen, Rural Capacity Building Program (HETI)
- Zachary Bryant, Master Public Health
- Felicia Cao, Doctor of Medicine
- Cecilia Correy, MPhil
- Kate Hocknull, Master Public Health
- Kathryn Ruth Kiefhaber, Doctor of Medicine
- Hannah Mogatra, Honours
- Rengen Parlane, Doctor of Medicine
- Taleah Reynolds, Grad Dip Indigenous Health Promotion
- Aiden Roberts, Doctor of Medicine
- Ameilia Russell, Master Public Health
- Aayushi Talwar, Doctor of Medicine
- Vincent Tran, Doctor of Medicine
- Tim Weatherall, Grad Dip Indigenous Health Promotion

Grant Funding

Granting body	Awardees	Project title	Grant total \$	Years	Status
Medical Research Future Fund	Lee K, Conigrave J, Wilson S, Hayman N, Conigrave K, Percival N, Chikritzhs T,	Making it easier for Aboriginal and Torres Strait Islander primary	\$3,466,749	2024-2028	New - Awarded in 2022

(MRFF) Primary Health Care Digital Innovations	Dawson A, Tracy M, Morley K, Doyle M, Fitts M, Weatherall T	health care services to screen for risky drinking and provide tailored feedback: adapting the Grog Survey App			
Research and Innovation for Global Health Transformation (RIGHT) Programme	Eddleston M, Gawarammana I, Wickramasuriya S, Street A, Dear J, Hassanian-Moghaddam H, McDonald R, Hovda KE, Buckley N, Konradsen F, Sandilands E, Karunaratne A, Weir C, Tse ML, Bhalla A, Marks C, Ghose A.	Preventing Deaths from Acute Poisoning in Low- and Middle-Income Countries.	\$9,219,076	2023-2028	New - Awarded in 2022
NHMRC Synergy Grant	Mitrou F, Zubrick S, Milroy H, Coffin J, Hamilton S, Brennan-Jones, C, Schurer S, Davis E, Richmond P, Passmore H. (Conigrave K is an Associate investigator)	Improving Aboriginal health by understanding the influence of early life environments and contacts with health and social service systems over time and across generations	\$5,000,000	2023-2027	New - Awarded in 2022
Ministry of Health NSW	Haber P, Doyle M, Day C, Lee K, Morley K, Buckley NA.	NSW Health PRSP - Prevention Research Program	\$500,000	2022-2027	New - Awarded in 2022
NHMRC Clinical Trial Cohort Study (2014980).	Lintzeris N, Lubman D, Doyle M, Dunlop A, Mills K, Harrod M, Arunogiri S, Malouf A, Haber M, Freeman A.	A randomised controlled trial of cannabidiol (CBD) in the treatment of cannabis dependence	\$2,120,137	2022-2026	New - Commencing in 2022
NHMRC Ideas Grant	Lee K, Wilson S, Conigrave K, Chikritzhs T, Hayman N, Dawson A, Ali R, Conigrave J, Fitts M	Better data on methamphetamines and other drugs among Indigenous Australians to inform policy and practice	\$2,614,769	2021-2025	Existing - Ongoing in 2022
ARC Discovery Project	Monds L, Takarangi, Chin, Montebello M; Pls: Semrad, Flowe	Investigating Memory Reliability in Intoxicated Witnesses of Crime	\$525,427	2022-2024	Existing - Ongoing in 2022
NHMRC Investigator Grant Level 3	Buckley NA	Applied research to prevent the epidemic of poisoning deaths	\$1,500,000	2022-2026	Existing - Ongoing in 2022
NHMRC Synergy Grant	Haber P, Morley K, Lawrence A, Manning V, Lubman D, McNally G, Millan Z, Arunogiri S	Linking clinical and basic science discovery to find new treatments for alcohol use disorder	\$5,000,000	2022-2026	Existing - Ongoing in 2022
MRFF Innovative Therapies for	Morley K, Mills K, Haber P, Lubman D, Teesson M,	A randomised, double-blind, controlled trial of MDMA assisted exposure	\$1,951,246	2022-2025	Existing - Ongoing in 2022

Mental Illness	Arunogiri S, Baillie A, Yong Yi Lee, Morse, Back S	therapy for comorbid alcohol use and post-traumatic stress disorder			
NHMRC Ideas Grant	Askew D, Abbott H, d'Antoine H, Poole N, Egert S, Schluter P, Liddle K. Ais: Spurling G, Moritz K, Conigrave K, Lee K, Hayes L, Toombs M, Brough M, Combo M, Percival N, Spiller V	Fetal Alcohol Spectrum Disorder Prevention and coordination of support for urban Aboriginal and Torres Strait Islander people and communities	\$726,743	2020-2023	Existing - Ongoing in 2022
NHMRC Project grant	L Stapinski, N Newton, M Snijder, M Doyle, K Champion, C Chapman. (Associate investigators: K Lee, K Conigrave, S Wilson)	Strong & Deadly Futures, a web-based alcohol and other drug prevention program for Aboriginal and Torres Strait Islander school students	\$1,907,377	2019-2024	Existing - Ongoing in 2022
NHMRC Global Alliance on Chronic Diseases	Dawson A, Glozier N, Conigrave C, Gawarammana I, LEE K, Pearson M, Buckley N, Jan S, Senarathna L, Abeyasinghe R	A randomised stepped wedge trial of the scaling up of a community-based alcohol education program in rural Sri Lankan villages and its effects on alcohol use, and associated harms, depression and social capital.	\$813,968	2018-2022	Existing - Ongoing in 2022
NHMRC Project grant	K Conigrave, P Haber, D Scrimgeour, N Hayman, K Lee, R Ivers, T Dobbins, D Gray, S Wilson	Increasing uptake of evidence-based management of unhealthy alcohol use in Aboriginal primary health care services	\$2,252,322	2016-2022	Existing - Ongoing in 2022
Ministry of Health NSW	Conigrave K, Conigrave J, Doyle M, Lee KSK, Dobbins T, Morley K.	Co-Creating Evidence from the Alcohol and other Drug Outcomes Register (AoDOR): Priority populations.	\$30,000	2021-2024	Existing - Ongoing in 2022
MRFF Research Grant	Y Clark, K Glover, A Rumbold, S Brown, K Conigrave, P Middleton, C Leane, K Towers, F Mensah, S Wilson	Working with Aboriginal families and health and social service providers to assess the feasibility of a novel care package to reduce cannabis and alcohol use and social stress in pregnancy	\$675,286	2021-2023	Existing - Ongoing in 2022
NHMRC Centre of Research Excellence	K. Conigrave, S. Wilson, A Shakeshaft, N Hayman, P. Haber, K. Lee, R. Ivers, C. Doran, A. Clifford.	A Centre for Research Excellence: Building Indigenous research capacity to find solutions to alcohol problems	\$2,495,984	2017-2023	Existing - Ongoing in 2022

NHMRC Project grant	J. Ward, R. McKetin, C Treloar, K. Conigrave, A Dunlop, E Wilkes, D Gray, B Quinn, H. Wand, N Ezard.	Novel Interventions to address methamphetamine in Aboriginal communities, including a randomised trial of a web based therapeutic tool used to treat dependence in clinical settings.	\$2,177,908	2016-2022	Existing - Ongoing in 2022
NHMRC Investigator Grant, Emerging Leadership 1	Doyle, M	Alcohol treatment for Aboriginal men in and out of prison	\$607,264	2022-26	Existing - Ongoing in 2022
NHMRC/Clinical Trials and Cohort Studies	Baillie A, Morley K, Haber P, Slade T	A randomised controlled trial of N-acetylcysteine for the treatment of alcohol use disorder	\$1,329,000	2021-2025	Existing - Ongoing in 2022
NHMRC Ideas Grant	Withall, Schofield, Ginnivan, Hwang; Als: Butler, Snoyman, Greenberg, Monds, Radford, Dingwall, Howie, Reutens	ASCAPE: Audio App-delivered Screening for Cognition and Age-related Health in Older Prisoners	\$844,050	2021-2023	Existing - Ongoing in 2022
Cystic Fibrosis Australia	Ooi, van Dorst, Katz, Sivam, Taylor, Haber, Jaffe, Thomas	Short chain fatty acids and gastrointestinal complications in cystic fibrosis	\$50,000	2021-2022	Existing - Ongoing in 2022
NSW Ministry of Health	Day CA, Roxburgh A, Haber PS, Reid SE, Roberts D, Lai H, Dietze P, Stoove M.	Health System Access and Patient Journey	\$30,000	2021	Existing - Ongoing in 2022
NSW Ministry of Health	Cairns R, Buckley NA, Roberts D, Brown J, Adamo G, Wright N	NSW Poisons Information Centre AusVapeSafety study	\$35,400	2021-2022	Existing - Ongoing in 2022
NSW Ministry of Health	Conigrave K, Conigrave J, Doyle M, Lee K, Dobbins T Morley K. (Als Haber P, Buckley N, Doran C, Wilson	Co-creating Evidence from the Alcohol and other Drugs Outcomes Register (AoDOR)	\$30,000	2021-2022	Existing - Ongoing in 2022
NHMRC	Schaffer A, Pearson SA, Buckley NA, Falster M, Brieger D, Abrahamowicz M, Daniels B	Disentangling the interrelationship between multimorbidity, multi-medicine use, and cardiovascular health	\$480,978	2021-2023	Existing - Ongoing in 2022
NSW Ministry of Health	Dunlop A, Roberts J, Lintzeris N, Haber P, Ezard N, Maher L, McEntyre, White B, Doyle M, Graham	How does long-acting depot buprenorphine impact on the high-risk post-release period for people with opioid dependence – The Release Study	\$798,652	2021-2023	Existing - Ongoing in 2022

Australian Research Data Commons	Cairns R, Wright N, Elliott R, Wylie C, Lynch AM, Dawson A, Greene S, Isoardi K, Armstrong J, Buckley N, Chiew A, Huynh A, Brown J.	Boosting public health research with a national poisoning dataset	\$525,000	2021-2023	New - Awarded in 2020
NHMRC	Lee KSK, Wilson S, Conigrave K, Chikritzhs T, Hayman N, Dawson A, Ali R, Conigrave J, Fitts M	Better data on methamphetamines and other drugs among Indigenous Australians to inform policy and practice.	\$2,614,769	2021-2025	Existing - Ongoing in 2022
NHMRC	Fatovich D, Soderstrom J, Dawson A, Alfred S, Greene S, Isoardi K, Pulbrook L, McCutcheon D, Oosthuizen	Emerging Drugs Network of Australia: a coordinated toxico-surveillance system of illicit drug use in Australia to enable rapid detection and harm reduction responses via an Early Warning System	\$3,722,731	2021 - 2023	Existing - Ongoing in 2022
NHMRC	Eastwood, Hiscock, Goldfield, Gillespie, Haber, de Leeuw, Katz, Page, Schneider, Cunich	A Centre of Research Excellence for Integrated Community Care of People with Complex Multi-morbidities	\$3,000,000	2020 - 2025	Existing - Ongoing in 2022
NHMRC	Pearson SA, Pratt N, Buckley N, Preen D, Degenhardt L, Van Gool K, Vajdic C, Jorm L, Wilson A, Henry D	NHMRC Centre of Research Excellence in Medicines Intelligence	\$2,500,000	2020 - 2025	Existing - Ongoing in 2021
NHMRC Ideas Grant	Askew D, Abbott H, d'Antoine H, Poole N, Egert S, Schluter P, Liddle K. (Conigrave K AI)	Fetal Alcohol Spectrum Disorder: prevention and coordination of support for urban Aboriginal and Torres Strait Islander people and communities	\$726,743	2020 - 2023	Existing - Ongoing in 2022
Edith Collins Seed Funding	Day, C.	Covid-19 related changes to opiate agonist treatment (COVAT) project	\$25,000	2020-2022	Existing - Ongoing in 2022
NSW Health	Dunlop, Bonevski, Lintzeris, Ezard, Gartner, Jackson, Rich, Oldmeadow, Searles, Nean, Harrod, Haber, Gill, Graham, Hallinan	Harmony study: A trial of the effectiveness of vaporised nicotine products (VNPs) for smoking cessation amongst NSW opiate agonist treatment (OAT) clients	\$950,000	2020 - 2022	Existing - Ongoing in 2022
Edith Collins Seed Funding	Morley KC	Harnessing novel technologies to examine mediators of suicidal ideation following admission for self-harm.	\$25,000	2020-2022	Existing - Ongoing in 2022

Edith Collins Seed Funding	Morley KC	Reducing recurrent self-poisoning and suicide risk by delivering interventions for substance use disorder by telehealth: The OPTIMISE project.	\$25,000	2020-2022	Existing - Ongoing in 2022
NHMRC Project Grant	Stapinski L, Newton N, Snijder M, Doyle M, Champion K, Chapman C. (Conigrave K is an Associate investigator).	Strong and Deadly Futures: A cluster RCT of a computerised school-based alcohol and drug prevention program for Aboriginal and Torres Strait Islander students	\$1,907,377	2019-2024	Existing - Ongoing in 2022
NHMRC	Morley KC (CIG) , Haber PS	The eCLIPSE Project: implementing evidence-based eHealth interventions for comorbid mental health and alcohol/other drug use problems into health and community settings	\$196,973	2019-2023	Existing - Ongoing in 2022
Suicide Prevention Australia	Morley KC (CIC)	Preventing repeated self-poisoning: A brief therapy text message intervention	\$523,614	2019-2022	Existing - Ongoing in 2022
NHMRC – Project Grant	Chitty, K, Pilgrim J, Cairns R, Schaffer A. (Als: Buckley NA, Pearson SA, Page A, Carter G, Wylie C, Raubenheimer J)	Health service and medicine utilisation before suicide: optimising suicide prevention using population-based linkage of routinely collected data	\$363,856	2019-2021	Existing - Ongoing in 2022
NHMRC/International Collaborations	Dawson, A., Conigrave, K., Buckley, N., Lee, K.	A randomised stepped wedge trial of the scaling up of a community-based alcohol education program in rural Sri Lankan villages	\$813,969	2018-2021	Existing - Ongoing in 2022
NHMRC - Project Grant	Degenhardt L, Pearson SA, Dobbins T, Gisev N, Currow D, Blyth F, Larney S, Dunlop A, Mattick R, Wilson A. (Als: Buckley N, Cohen, Coory, Farrell M, Haber P, Ivers R)	Combating escalating harms associated with pharmaceutical opioid use	\$969,205	2018-2021	Existing - Ongoing in 2022
NHMRC Practitioner Fellowship	Conigrave KM	Working with Indigenous services and communities to reduce the harms from alcohol	\$474,512	2017-2022	Existing - Ongoing in 2022

NSW Ministry Health	Haber PS	Opioid Treatment Accreditation Course (OTAC)	\$650,000	2018-2021	Existing - Ongoing in 2022
NHMRC/MRF F Practitioner Fellowship	Haber PS	Novel treatment for alcohol use disorder	\$417,500	2019-2023	Existing - Ongoing in 2022
NHMRC/Project Grant	Ward, J., Ezard, N., Treloar, C., Mcketin, R., Wilkes, E., Dunlop, A., Conigrave, K., Gray, D., Quinn, B., Wand, H.	Novel interventions to address methamphetamines in Aboriginal communities	\$2,234,452	2016-2021	Existing - Ongoing in 2022
		Total	\$ 69,848,037		
		Total new funding	\$ 20,305,962		

Books & book chapters (n = 3)

1. Buckley N, Calear A, Cairns R, Reily N, Tang S, McCallum S, Christensen H. Independent expert report on the risks of intentional self-poisoning with paracetamol. **TGA Sept 2022**. Available at <https://www.tga.gov.au/sites/default/files/2022-09/independent-expert-report-on-the-risks-of-intentional-self-poisoning-with-paracetamol.docx>
2. Roberts D, Buckley NA. Paraquat/Diquat poisoning in: **UpToDate**, Basow, DS (Ed), UpToDate, Waltham, MA; latest version June 2022.
3. Buckley N. Organophosphorus poisoning. **BMJ Knowledge/ePoCrates** (commissioned monograph) 2022. <https://online.epocrates.com/u/2911852/Organophosphate+poisoning/>

Journals articles (n = 93)

1. Liu K, Terry Y, Masson S, Fateen W, Schwantes-An T-H, McCaughan GW, Aithal G, Seth D. Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol-related cirrhosis patients. **Liver Cancer International** 2022, 3: 99-104.
2. Whitfield JB, Seth D, Morgan TR. All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank. **Alcohol Clin Exp Res** 2022, 46(12):2245-2257. DOI: 10.1111/acer.14968.
3. Whitfield JB, Schwantes-An T-H, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet J-M, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Mullhaupt B, Nagy L, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trepo E, Morgan TR, Seth D: A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. **J Hepatology** 2022, 76(2):275-82.
4. Isbister GK, Jenkins S, Noutsos T, Isoardi KZ, Soderstrom J, Buckley NA. The diagnostic value of D-Dimer in Australian snake envenoming (ASP-29). **Medical Journal of Australia** 2022;217(4):203-7. doi: 10.5694/mja2.51589.
5. Noghrehchi F, Raubenheimer J, Dawson AH, Buckley NA. Role of age-sex as underlying risk factors for death in acute pesticide self-poisoning: A prospective cohort study. **Clinical Toxicology** 2022;60(2):184-190. doi: 10.1080/15563650.2021.1921186

6. Wijerathna TM, Buckley NA, Gawarammana IB, Raubenheimer J, Shahmy S, Chathuranga U, Palangasinghe C, Shihana F, Dissanayake AMSDM, Mohamed F. Epidemiology and renal injury following Methyl-4-chlorophenoxyacetic acid (MCPA) poisoning. **Scientific Reports** 2022; 12:21940. doi: 10.1038/s41598-022-25313-z.
7. Chitty KM, Raubenheimer J, Kirby K, Cairns R, Buckley NA. Deliberate self-poisoning in Australian adolescents is increased on school days. **Journal of Psychiatric Research** 2022; 148: 103–109. doi: 10.1016/j.jpsychires.2022.01.045
8. Perananthan V, Wijerathna TM, Mohamed F, Gawarammana IB, Dawson AH, Buckley NA. Circulating intestinal fatty acid binding protein and gastrointestinal toxicity in Russell’s Viper envenomation. **Clinical Toxicology** 2022;60(3):311-318. doi:10.1080/15563650.2021.1965160.
9. Schaffer A, Bruno C, Buckley NA, Cairns R, Litchfield M, Paget S, Zoega H, Nassar N, Pearson SA. Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children. **Paediatric and Perinatal Epidemiology** 2022; 36:726–737. doi:10.1111/ppe.12870.
10. Daniels B, Schaffer A, Buckley NA, Bruno C, Jun M, Pearson SA, Zoega H. The impact of new prescribing restrictions for proton pump inhibitors in Australia: an evaluation using interrupted time series analysis. **Pharmacoepidemiology and Drug Safety** 2022;31(3):370-378. doi: 10.1002/pds.5395.
11. Nendick E, Mohamed F, Raubenheimer J, Gawarammana I, Buckley NA, Eddleston M. Acute Fungicide Self-Poisoning - A Prospective Case Series. **Clinical Toxicology** 2022;60(10):1106-12. doi: 10.1080/15563650.2022.2105710.
12. Dassanayake TL, Weerasinghe VS, Gawarammana I, Cooper P, Buckley NA. Changes of attention-related brain activity over 6 months after acute organophosphate pesticide poisoning: a prospective follow-up study. **Clinical Toxicology** 2022; 60(5): 576-584. doi: 10.1080/15563650.2021.2010742.
13. Schaffer AL, Brett J, Buckley NA, Pearson SA. Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use. **Pain** 2022; 163: e614–e621. doi:10.1097/j.pain.0000000000002433.
14. Chan BS, Isbister GK, Chiew AL, Isoardi K, Buckley NA. Clinical Experience with Titrating Doses of Digoxin Antibodies in Acute Digoxin Poisoning (ATOM-6). **Clinical Toxicology** 2022; 60(4):433-439. doi: 10.1080/15563650.2021.1968422.
15. Chiew AL, Raubenheimer JE, Berling I, Buckley NA, Becker T, Chan B, Brett J. Just “nanging” around - nitrous oxide abuse. A retrospective case series and review of internet searches, social media posts and the coroner’s database. **Internal Medicine Journal** 2022;52: 1724–1732. doi: 10.1111/imj.15391
16. Pai K, Buckley NA, Isoardi KZ, Isbister GK, Becker T, Chiew AL, Cairns R, Brown J, Chan BS. Optimising Alkalinisation and its effect on QRS Narrowing in Tricyclic Antidepressant Poisoning. **British Journal of Clinical Pharmacology** 2022;88:723–733. doi: 10.1111/bcp.15008
17. Rambabu L, Mohamed F, Raubenheimer J, Roberts MS, Buckley NA, MacKenzie L, Gawarammana IB, Eddleston M. Acute phenthoate self-poisoning: a prospective case series. **Clinical Toxicology** 2022;60(2):214-220. doi: 10.1080/15563650.2021.1917596
18. Rahman S, Trussell A, Pearson SA, Buckley NA, Karanges EA, Cairns R, Litchfield M, Todd A, Gisev N. Trends in fentanyl utilisation and fatal overdose across Australia, 2003-2015. **Drug and Alcohol Review** 2022;41(2):435-443. doi:10.1111/dar.13391.
19. Mirabella J, Ravi D, Chiew A, Buckley NA, Chan BS. Prescribing Trend of Tapentadol in a Sydney Local Health District. **British Journal of Clinical Pharmacology** 2022; 88:3929–3935. doi: 10.1111/bcp.15448.

20. Chiew AL, Buckley NA. The Serotonin Toxidrome: shortfalls of current diagnostic criteria for related syndromes. **Clinical Toxicology** 2022;60(2):143-158. doi: 10.1080/15563650.2021.1993242.
21. Ling R, White B, Roberts J, Cretikos M, Howard MV, Haber PS, Lintzeris N, Reeves P, Dunlop AJ, Searles A. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model. **BMC Health Serv Res.** 2022 Nov 8;22(1):1326. doi: 10.1186/s12913-022-08687-8.
22. Maddern XJ, Walker LC, Campbell EJ, Arunogiri S, Haber PS, Morley K, Manning V, Millan EZ, McNally GP, Lubman DI, Lawrence AJ. Can we enhance the clinical efficacy of cognitive and psychological approaches to treat substance use disorders through understanding their neurobiological mechanisms? **Neurosci Biobehav Rev.** 2022 Nov;142:104899. doi: 10.1016/j.neubiorev.2022.104899. Epub 2022 Sep 29. PMID: 36183863..
23. Merrick TT, Louie E, Cleary M, Molloy L, Baillie A, Haber P, Morley KC. A systematic review of the perceptions and attitudes of mental health nurses towards alcohol and other drug use in mental health clients. **Int J Ment Health Nurs.** 2022 Dec;31(6):1373-1389. doi: 10.1111/inm.13043. Epub 2022 Jul 31. PMID: 35909095
24. Louie E, Giannopoulos V, Baillie A, Uribe G, Wood K, Teesson M, Haber PS, Morley KC. Relationship between clinician-level attributes and implementation outcomes from the Pathways to Comorbidity Care training program. **BMC Med Educ.** 2022 Aug 5;22(1):605. doi: 10.1186/s12909-022-03671-6. PMID: 35931994
25. Chitty KM, Cvejic RC, Heintze T, Srasuebku P, Morley K, Dawson A, Carter G, Dinh M, Buckley NA, Trollor JN. The Association Between Problematic Use of Alcohol and Drugs and Repeat Self-Harm and Suicidal Ideation. **Crisis.** 2022 Sep 8. doi: 10.1027/0227-5910/a000880. Epub ahead of print. PMID: 36073254.
26. Louie E, Giannopoulos V, Uribe G, Wood K, Teesson M, Childs S, Baillie A, Haber PS, Morley KC. Geographical variation in implementation of the Pathways to Comorbidity Care program in Australian drug and alcohol services. **JBI Evid Implement.** 2022 Oct 5. doi: 10.1097/XEB.0000000000000344. Epub ahead of print. PMID: 36378096.
27. Uribe Guajardo MG, Baillie A, Louie E, Giannopoulos V, Wood K, Riordan B, Haber P, Morley K. The evaluation of the role of technology in the pathways to comorbidity care implementation project to improve management of comorbid substance use and mental disorders. **J Multimorb Comorb.** 2022 Apr doi: 10.1177/26335565221096977. PMID: 35586033;
28. Josifovski N, Shand F, Morley K, Chia J, Henshaw R, Petrie K, Reda B, Li E, Theobald A, Onie S, Torok M, Berrouguet S, Batterham PJ, Carter G, Haber P, Christensen H, Larsen ME. A pilot study of a text message and online brief contact intervention following self-harm or a suicide attempt: A mixed methods evaluation. **Gen Hosp Psychiatry.** 2022 May-Jun;76:1-2. doi: 10.1016/j.genhosppsy.2022.03.002. Epub 2022 Mar 11. PMID: 35303519.
29. Morley KC, Louie E, Hurzeler T, Baillie A, Dore G, Phung N, Haber PS. Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence. **Front Glob Womens Health.** 2022 Mar 29;3:807269. doi: 10.3389/fgwh.2022.807269. PMID: 35425938
30. Louie E, Giannopoulos V, Baillie A, Uribe G, Wood K, Teesson M, Childs S, Rogers D, Haber PS, Morley KC. Barriers and Facilitators to the Implementation of the Pathways to Comorbidity Care (PCC) Training Package for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings **Frontiers in Health Services: Implementation Science**, 17(4):304-312
31. Morley KC, Logge WB, Riordan BC, Brannon S, Haber PS, Conner TS. Daily experiences of hangover severity and food consumption in young adults. **Br J Health Psychol.** 2022 May;27(2):468-483. doi: 10.1111/bjhp.12555. Epub 2021 Aug. PMID: 34431182
32. Logge W, Baillie A, Haber P, Towers E, Riordan BC, Morley K. Sex differences in the interrelations between stress, craving and alcohol consumption across individuals and time

- during baclofen treatment for alcohol dependence. **Addict Behav.** 2023 Jan;136:107462. doi: 10.1016/j.addbeh.2022.107462. Epub 2022 Aug 11. PMID: 36084413.
33. Purcell-Khodr G, Webster E, Harrison K, Dawson A, Lee K, Conigrave K. The Importance of Culture in Alcohol Care: Listening to First Nations staff in Australian Aboriginal Community Controlled Health Services. **The International Indigenous Policy Journal.** 2022;13(3):1-29.
 34. Lee K, Bullen LM, Zheng C, Dawson A, Munro A, Conigrave KM. Beliefs and attitudes of drug and alcohol clinicians when considering referral of Aboriginal clients to involuntary drug and alcohol treatment: A qualitative study. **Drug and Alcohol Review.** 2023;42(1):169-80. (First published 04 October 2022)
 35. Stearne AE, Lee K, Allsop S, Shakeshaft A, Wright M. Self-determination by First Nations Australians in alcohol policy: lessons from Mbantua/Alice Springs (Northern Territory, Australia). **International Journal of Drug Policy.** 2022;108:103822.
 36. Lee K, Wilson S, Stearne AE, Hayman N, Conigrave JH, Doyle M, Bullen L, Weatherall TJ, James D, Reynolds T, Perry J. Walking side-by-side: Supporting Aboriginal and Torres Strait Islander Australians to lead the way in alcohol research. **Drug and Alcohol Review.** 2023;42(2):241-7. (first published 04 August 2022)
 37. Conigrave JH, Lee K, Haber PS, Vnuk J, Doyle MF, Conigrave KM. More than three times as many Indigenous Australian clients at risk from drinking could be supported if clinicians used AUDIT-C instead of unstructured assessments. **Addiction Science & Clinical Practice.** 2022;17(1):23.
 38. Dzidowska M, Raubenheimer JE, Dobbins TA, Lee K, Hayman N, Vnuk J, Haber P, Conigrave KM. Effects of service-wide support on regularity of alcohol screening of clients in Australian Aboriginal and Torres Strait Islander Community Controlled Health Services: a cluster randomised trial. **Addiction science & clinical practice.** 2022;17(1):1-2.
 39. Routledge K, Snijder M, Newton N, Ward J, Doyle M, Chapman C, Champion KE, Lees B, Bock SG, Wang Y, Olthuis PW. Acceptability and feasibility of Strong & Deadly Futures, a culturally-inclusive alcohol and drug prevention program for Aboriginal and/or Torres Strait Islander secondary students. **SSM-Mental Health.** 2022;2:100073.
 40. Stearne AE, Lee K, Allsop S, Shakeshaft A, Wright M. First Nations Australians' self-determination in health and alcohol policy development: a Delphi study. **Health Research Policy and Systems.** 2022;20(1):12.
 41. Stapinski L, Routledge K, Snijder M, Doyle M, Champion K, Chapman C, Ward J, Baumgart A, Lee K, Teesson M, Newton N. A web-based alcohol and other drug prevention program (Strong & Deadly Futures) for Aboriginal and Torres Strait Islander school students: protocol for a cluster randomized controlled trial. **JMIR Research Protocols.** 2022;11(1):e34530.
 42. Conigrave JH, Wilson S, Conigrave KM, Chikritzhs T, Hayman N, Dawson A, Ali R, Perry J, Fitts MS, Degenhardt L, Doyle M, Lee K. 'The Drug Survey App': a protocol for developing and validating an interactive population survey tool for drug use among Aboriginal and Torres Strait Islander Australians. **Addiction Science & Clinical Practice.** 2022;17(1):1-1.
 43. Gendera S, Treloar C, Reilly R, Conigrave KM, Butt J, Roe Y, Ward J. 'Even though you hate everything that's going on, you know they are safer at home': The role of Aboriginal and Torres Strait Islander families in methamphetamine use harm reduction and their own support needs. **Drug and Alcohol Review.** 2022;41(6):1428-39.
 44. Noroozi A, Conigrave KM, Mirrahimi B, Bastani P, Charkhgard N, Salehi M, Narenjiha H, Vaziri A, Kebriaeezadeh A. Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran. **Drug and Alcohol Review.** 2022;41(2):419-29.
 45. Doyle MF, Guthrie J, Butler T, Shakeshaft A, Conigrave K, Williams M. Opportunities for intervention for alcohol and other drug use problems for men before prison: A qualitative study. **Health Promotion Journal of Australia.** 2022.

46. Al Ansari M, Dawson A, Conigrave K. Alcohol among young people in Iraq: a systematic scoping review. **Discover Psychology**. 2022;2(1):16.
47. Conigrave JH, Conigrave KM, Wilson S, Lee K. Indigenous Australian drinking risk: Comparing risk categorisations based on recall of recent drinking occasions to AUDIT-C screening in a representative sample. **Drug and Alcohol Review**. 2022;41(3):616-24.
48. Doyle MF, Williams M, Butler T, Shakeshaft A, Conigrave K, Guthrie J. Perspectives of prisoners on alcohol and other drug group treatment approaches. **International Journal of Prisoner Health**. 2022;18(1):55-65.
49. Al Ansari M, Dawson A, Room R, Abdulzahra M, Conigrave KM. Alcohol and University Students in Iraq: Attitudes, Availability, and Use. **Journal of Muslim Mental Health**. 2022;16(2).
50. Zheng C, Conigrave JH, Conigrave KM, Wilson S, Perry J, Chikritzhs TN, Fitts MS, Lee K. Patterns of drinking in Aboriginal and Torres Strait Islander peoples as self-reported on the Grog Survey App: a representative urban and remote sample. **Drug and Alcohol Review**. 2022;41(1):114-24.
51. Weatherall TJ, Conigrave JH, Conigrave KM, Perry J, Wilson S, Room R, Fitts MS, Hayman N, Lee K. Prevalence and correlates of alcohol dependence in an Australian Aboriginal and Torres Strait Islander representative sample: using the Grog Survey App. **Drug and Alcohol Review**. 2022;41(1):125-34.
52. Bradshaw EL, Conigrave JH, Steward BA, Ferber KA, Parker PD, Ryan RM. A meta-analysis of the dark side of the American dream: Evidence for the universal wellness costs of prioritizing extrinsic over intrinsic goals. **Journal of Personality and Social Psychology**. 2022.
53. James DB, Lee K, Dronavalli M, Courtney RJ, Conigrave KM, Conigrave JH, Shakeshaft A. Predictors of length of treatment, discharge reason, and re-admission to Aboriginal alcohol and other drug residential rehabilitation services in New South Wales, Australia. **Drug and Alcohol Review**. 2022;41(3):603-15. doi: 10.1111/dar.13388. Epub 2021 Oct 13. PMID: 34644427.
54. Dunlop AJ, White B, Roberts J, Cretikos M, Attalla D, Ling R, Searles A, Mackson J, Doyle MF, McEntyre E, Attia J. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. **Addiction**. 2022;117(2):382-91.
55. Lee K, Wilson S, Stearne A, Hayman N, Conigrave JH, Doyle MF, Bullen L, Weatherall TJ, James Douglas B, Reynolds T, Perry J, Conigrave KM. Walking side-by-side: supporting Aboriginal and Torres Strait Islander Australians to lead the way in alcohol research. **Drug Alcohol Rev**. 2022;doi.org/10.1111/dar.13523
56. Doyle MF, Dsouza B, Conigrave KM. Perceived impacts of a prison-based drug treatment program on planning for release: A qualitative study. **Drug and Alcohol Review**. 2022; 41:S18.
57. Freeburn B, Loggins S, Lee K, Conigrave K. Coming of age: 21 years of providing opioid substitution treatment within an Aboriginal community-controlled primary health service. **Drug Alcohol Rev**. 2022;41(1):260-4.
58. Dzikowska M, Lee K, Conigrave JH, Dobbins TA, Hummerston B, Wilson S, Haber PS, Gray D, Conigrave KM. Support for Aboriginal health services in reducing harms from alcohol: 2-year service provision outcomes in a cluster randomized trial. **Addiction** [Internet]. 2022;117(3):796-803.
59. Watt J, Haber P, Conigrave K. How to Treat: Unhealthy alcohol use. **Australian Doctor**. 2022;13-20.
60. Qiang S, Mohamed F, Mackenzie L, Roberts MS. Rapid determination of polyethoxylated tallow amine surfactants in human plasma by LC-MS/MS. **Talanta**. 2022 Nov 19;254:124115. doi: 10.1016/j.talanta.2022.124115. Epub ahead of print. PMID: 36481395.
61. Deuster E, Tomenson JA, Mohamed F, Gawarammana I, Buckley NA, Wilks MF, Eddleston M. Dose ingested, vomiting, and outcome in patients ingesting a standard paraquat 20SL

- formulation. **Clinical Toxicology**. 2022 Dec 21:1-10. doi: 10.1080/15563650.2022.2142601. Epub ahead of print. PMID: 36541442.
62. Dhanarisi J, Perera S, Wijertahna T, Gawarammana I, Eddleston M, Mohamed F. Relationship between alcohol co-ingestion and clinical outcome in pesticide self-poisoning: a systematic review and a meta-analysis. **Alcohol and Alcoholism**, 2022; agac045
 63. Schölin L, Weerasinghe M, Agampodi S, Chathurange U, Rajapaksha S, Holloway A, Norrie J, Mohamed F, Eddleston M, Pearson M. (March 2022) Involvement of alcohol in injury cases in rural Sri Lanka: prevalence and associated factors among in-patients in three primary care hospitals. **BMC Public Health**, 22(1)
 64. Egan L, Riordan B, Newling G, Uthurralt N., Day, CA. (2022) Sydney's inner-west is brimming with micro-breweries, should we be worried and what does it mean for research and policy? **Drug and Alcohol Review**. DOI: 10.1111/dar.13611
 65. Day CA, Salmon A, Jauncey M, Bartlett M, Roxburgh A. (2022) Twenty years at the Uniting Medically Supervised Injecting Centre, Sydney Australia: addressing the remaining questions. **Medical Journal of Australia**, 271(8): 385-387 DOI:10.5694/mja2.51716
 66. Reid SE, Day CA, White N, Harrison, C, Haber PS, Bayram C. (2022) Patterns of opioid prescribing in Australian General Practice. **BMC Primary Care**; 23: 171. <https://doi.org/10.1186/s12875-022-01783-y>
 67. Coupland H, Henderson C, Pritchard-Jones, J, Kao, S, Sheils S, Nagy R, O'Donnell M, Haber, PS, Day CA. (2022) "Setting foot in private spaces: Extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines. **BMC Harm Reduction Journal**; 19:56. doi.org/10.1186/s12954-022-00640-6
 68. Uthurralt, N, McGlenn, A, O'Donnell, M, Haber, PS. Day, CA. (2022). The impact of 24-hour syringe dispensing machine on use of face-to-face needle and syringe program and targeted primary healthcare clinic for people who inject drugs. **Australian and New Zealand Journal of Public Health**, 46(4): 524-526. <http://doi.org/10.1111/1753-6405.13267>
 69. Winter DT, Geiger B, Day, CA. (2022) A comment on participant reimbursement within Australian drug and alcohol research. **Drug and Alcohol Review**. 41: 1484-1486 <https://doi.org/10.1111/dar.13452>
 70. Coupland H, Haber P, Day CA, Pritchard-Jones J, McKee K, George J, McCaughan G. (2022) "It's another thing to deal with": Resisting hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia. **Drug and Alcohol Review**. DOI: 10.1111/dar.13414
 71. Logge WB, Morley KC, Haber PS. GABAB Receptors and Alcohol Use Disorders: Clinical Studies. **Curr Top Behav Neurosci**. 2022;52:195-212. doi:10.1007/7854_2020_182. PMID: 33580440.
 72. Evans NT, Williams N, Perananthan V, Lugg W, Dawson AH, Osborn DA. Neonatal serotonin toxicity. **J Paediatr Child Health**. 2022 Jan;58(1):189-190. doi: 10.1111/jpc.15443. Epub 2021 Mar 16. PMID: 33724598
 73. Fitts MS, Burchill R, Wilson S, Palk GR, Clough AR, Conigrave KM, Slade T, Shakeshaft A, Lee KSK. Drink driving among Aboriginal and Torres Strait Islander Australians: What has been done and where to next? **Drug Alcohol Rev**. 2022 Sep;41(6):1412-1417. doi: 10.1111/dar.13418. Epub 2021 Dec 19. PMID: 34927302
 74. Smith JL, Soderstrom J, Dawson A, Alfred S, Greene S, Isoardi K, McCutcheon D, Oosthuizen F, Ezard N, Burcham J, Fatovich DM; EDNA Investigators. The Emerging Drugs Network of Australia: A toxicosurveillance system of illicit and emerging drugs in the emergency department. **Emerg Med Australas**. 2022 Feb;34(1):58-64. doi: 10.1111/1742-6723.13839. Epub 2021 Aug 12. PMID: 34382338.
 75. Siefried KJ, Ezard N, Christmass M, Haber P, Ali R; NCCRED Methamphetamine and Emerging Drugs Clinical Research Network Working Group. A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia. **Drug Alcohol Rev**. 2022 Feb;41(2):309-319. doi: 10.1111/dar.13350. Epub 2021 Jul 8. PMID: 34237176

76. Sahinovic A, Irwin C, Doohan PT, Kevin RC, Cox AJ, Lau NS, Desbrow B, Johnson NA, Sabag A, Hislop M, Haber PS, McGregor IS, McCartney D. Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. **Sports Med Open**. 2022 Mar 2;8(1):27. doi:10.1186/s40798-022-00417-y. PMID: 35235092; PMCID: PMC8891421.
77. Moensted ML, Buus N, Day CA. Examining Relational Dimensions of Service Encounters for Disadvantaged People Who Use Drugs. **J Addict Nurs**. 2022 Jul-Sep01;33(3):159-167. doi: 10.1097/JAN.0000000000000479. PMID: 36041158.
78. Graham S, Blaxland M, Bolt R, Beadman M, Gardner K, Martin K, Doyle M, Beetson K, Murphy D, Bell S, Newman CE, Bryant J. Aboriginal peoples' perspectives about COVID-19 vaccines and motivations to seek vaccination: a qualitative study. **BMJ Glob Health**. 2022 Jul;7(7):e008815. doi:10.1136/bmjgh-2022-008815. PMID: 35858705; PMCID: PMC9304971.
79. Coupland H, Day C, Haber P, Pritchard-Jones J, McKee K, George J, McCaughan G. Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. **Drug Alcohol Rev**. 2022 Mar;41(3):706-714. doi: 10.1111/dar.13414. Epub 2021 Nov 28. PMID:34839561.
80. Nash E, Walker E, Watt J, Sannikova A, Dawson A, Anderson T, Sheather M, Jewitt J, Linnegar P, Hutchings O, Haber PS. Management of alcohol and other drug issues in Special Health Accommodation during the COVID-19 Delta variant outbreak in Sydney, 2021. **Drug Alcohol Rev**. 2022 Sep;41(6):1319-1321. doi:10.1111/dar.13506. Epub 2022 Jun 21. PMID: 35730108
81. Dawson A. Physostigmine should be used more readily for antimuscarinic toxicity: PRO. **Br J Clin Pharmacol**. 2022 Jan;88(1):58-60. doi:10.1111/bcp.15120. Epub 2021 Nov 16. PMID: 34705298
82. Chan BS, Sheppeard V, Dawson AH. E-cigarette or vaping product use-associated lung injury in an adolescent. **Med J Aust**. 2022 Apr 18;216(7):374. doi: 10.5694/mja2.51473. Epub 2022 Mar 24. PMID: 35324022
83. Graham S, Martin K, Beadman M, Doyle M, Bolt R. Our relationships, our values, our culture - Aboriginal young men's perspectives about sex, relationships and gender stereotypes in Australia. **Cult Health Sex**. 2023 Mar;25(3):304-319. doi: 10.1080/13691058.2022.2039776. Epub 2022 Feb 22. PMID: 35192437.
84. Isbister GK, Noutsos T, Jenkins S, Isoardi KZ, Soderstrom J, Buckley NA. D-dimer testing for early detection of venom-induced consumption coagulopathy after snakebite in Australia (ASP-29). **Med J Aust**. 2022 Aug 15;217(4):203-207. doi: 10.5694/mja2.51589. Epub 2022 Jun 7. PMID: 35670073.
85. Lin A, Wong K, Visser SK, Jo H, Al-Hindawi Y, Kosbab-Jackson K, Cocks M, Volovets A, Haber P, Hammond K, Taylor N, Yozghatljan V, Lau EM, Marshall NS, Aquino-Salomon T, Sivam S. Diagnosis of cystic fibrosis in adults: Australian Cystic Fibrosis Data Registry data, 2000-2019. **Med J Aust**. 2023 Feb 20;218(3):138-139. doi: 10.5694/mja2.51797. Epub 2022 Dec 1. PMID: 36453811
86. Rafizadeh A, Bhalla A, Sharma N, Kumar K, Zamani N, McDonald R, Roberts DM, Hassanian-Moghaddam H. Evaluating new simplified assays for harm reduction from methanol poisoning using chromotropic acid kits: An analytical study on Indian and Iranian alcoholic beverages. **Front Public Health**. 2022;10: 983663.
87. Ghannoum M, Roberts DM, Goldfarb DS, Heldrup J, Anseeuw K, Galvao TF, Nolin TD, Hoffman B, Lavergne V, Meyers P, Gosselin S, Botnaru T, Mardini K, Wood DM. Extracorporeal treatment for methotrexate poisoning: Systematic review and recommendations from the EXTRIP workgroup. **Clin J Am Soc Neph** 2022; 17(4): 602-622
88. Bouchard J, Yates C, Calello DP, Gosselin S, Roberts DM, Lavergne V, Hoffman RS, Ostermann M, Peng A, Ghannoum M; EXTRIP Workgroup. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. **Am J Kidney Dis**. 2022 Jan;79(1):88-104

89. Beaulieu J, Roberts DM, Gosselin S, Hoffman RS, Lavergne V, Hovda KE, Megarbane B, Lung D, Thanacoody R, Ghannoum M. Treating ethylene glycol poisoning with alcohol dehydrogenase inhibition, but without extracorporeal treatments: a systematic review. *Clinical Toxicology (Phila)* 2022; 60(7): 784-797
90. Roberts DM, Hoffman RS, Brent J, Lavergne V, Hovda KE, Porter WH, McMartin KE, Ghannoum M. The serum glycolate concentration: its prognostic value and its correlation to surrogate markers in ethylene glycol exposures. *Clinical Toxicology (Phila)* 2022; 60(7):798-807
91. Murnion BP, Roberts DM. Responding to the rising number of suicides using barbiturates. *Med J Aust.* 2022; 216(4): 187-188.
92. Jamshidi N, Dhaliwal N, Hearn D, McCalman C, Wenzel R, Koutsogiannis Z, Roberts DM. Life-threatening barium carbonate poisoning managed with intravenous potassium, continuous veno-venous haemodialysis and endoscopic removal of retained ceramic glazes. *Clin Toxicol (Phila).* 2022 Aug;60(8):974-978.
93. Hlusicka J, Sevela S, Smid V, Sestak V, Roberts DM. Methaemoglobinaemia and oesophageal burns after accidental ingestion of an alkyl nitrite. *Clin Toxicol (Phila).* 2022; 60(11): 1288-1290.

Research letters/case/other reports (n=9)

1. Chiew AL, Buckley NA. Comment on “The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes”. **Clinical Toxicology** 2022;60(9):1081-2. doi: 10.1080/15563650.2022.2101472
2. Chan BS, Buckley NA. Comment on – clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning **Clinical Toxicology** 2022; 60(4):448. doi: 10.1080/15563650.2021.2013497
3. Tan H, Stathakis P, Varghese B, Buckley NA, Chiew AL. Delayed Acetaminophen Absorption resulting in Acute Liver Failure. **Case reports in Critical Care** 2022; 2, Article ID 3672248, 6 pages. doi: 10.1155/2022/3672248
4. Chan BS, Buckley NA. Authors' reply to comment on: clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. **Clinical Toxicology (Phila).** 2022 Apr;60(4):548. doi: 10.1080/15563650.2021.2013497.
5. Whitfield JB, Morgan TR, Seth D. Reply to: External validation of a genetic risk score that predicts development of alcohol-related cirrhosis. **J Hepatology** 2022, [https://authors.elsevier.com/sd/article/S0168-8278\(22\)03055-0](https://authors.elsevier.com/sd/article/S0168-8278(22)03055-0)
6. Rosenbaum E, Bode MJF, Roberts DM. Death from severe, refractory methaemoglobinaemia. A case report to illustrate an increasingly frequent manifestation of deliberate self-poisoning. *Emerg Med Austral* 2022; 34(4): 654-655.
7. Bode MJF, Huber J, Roberts DM. Decision-making in suicide: when is the patient not for resuscitation? *Emerg Med Austral* 2022; 34(3): 473-474. doi: 10.1111/1742-6723.13977. [case report]
8. Freeburn B, Lee K, Conigrave K. Patients from Aboriginal and Torres Strait Islander communities. In: NSW Ministry of Health. Management of withdrawal from alcohol and other drugs: Clinical Guidance. Sydney: **NSW Ministry of Health**; 2022. p. 90-2. www.health.nsw.gov.au/aod/professionals/Publications/Clinical-guidance-withdrawal-alcohol-and-other-drugs.pdf
9. Freeburn B, Lee K, Conigrave K. Patients from Aboriginal and Torres Strait Islander communities. In: NSW Ministry of Health, editor. Management of Withdrawal from Alcohol and Other Drugs: Handbook. Sydney, NSW: **NSW Ministry of Health**; 2022. p. 46-8. www.health.nsw.gov.au/aod/professionals/Publications/handbook%20managing%20withdr awal%20alcohol%20and%20other%20drugs.pdf

Original research presentations (n = 24)

1. Lee KS, Wilson S, Conigrave JH, Perry J, Zheng C, Fitts MS, Conigrave KM. Re-thinking how we ask Aboriginal and Torres Strait Islander peoples about their drinking. [conference presentation] **Drug and Alcohol Review**. 2022;41:S11-S12.
2. Camacho X, Schaffer A, Buckley N, Pratt N, Brett J, Henry D, Pearson SA. Trends in dispensing and utilisation of sustained release tapentadol in Australia. **International Population Data Linkage Conference 2022. International Journal of Population Data Science** 2022;7:(3)
3. Schaffer AL, Buckley NA, Schumann JL, Lim J, Cairns R, Chitty KM. Patterns of Psychotropic Medicine Use and Initiation in The Year Prior to Death by Suicide: A Population-Based Study. **ICPE 2022, Copenhagen August 2022.**
4. Camacho X, Schaffer A, Buckley N, Pratt N, Henry D, Pearson SA. Trends in dispensing and utilisation of tapentadol in Australia. **ICPE 2022, Copenhagen August 2022**
5. Cairns R, Buckley NA. The impact of Pharmacist Only up-scheduling of modified release paracetamol on poisonings in Australia. **TAPNA, Newcastle May 2022**
6. Chiew AL, Isoardi KZ, Chan BS, Buckley NA, Isbister GK. Serotonin toxicity following acute lamotrigine overdose: a prospective series. **European Association of Poisons Centres & Clinical Toxicology Scientific meeting, Tallinn May 2022. Clinical Toxicology** 2022;60(6-S1):88-89.
7. White B, Little S, Haber PS, Roberts J, Lintzeris N, Dunlop AJ. Patient-reported outcomes of subcutaneous depot buprenorphine treatment in Australian correctional centres. **Lisbon Addictions 2022, 22-25 November**
8. White B, Little S, Haber PS, Roberts J, Lintzeris N, Dunlop AJ. Patient-reported outcomes of subcutaneous depot buprenorphine treatment in Australian correctional centres. **Drug and Alcohol Review** 2022; 41 (S1)
9. Kim S, White B, Roberts J & Day C. A Prevalence of substance use among incarcerated pregnant women in NSW. **Drug and Alcohol Review** 2022; 41 (S1)
10. Braude R, Moensted M, Reid S, White B, Coupland H, Day C. Examining the benefits of an Australian mothers' group specifically for women with substance use disorders: a qualitative analysis. Presented at 22nd **International Conference on Integrated Care, Odense, Denmark, 23-25 May 2022.**
11. Day C. Automatic Dispensing Machines – the Sydney experience. Invited presentation to Emory University Atlanta US, **Drug Safety Task Force, Atlanta, Georgia, USA** (virtual). March 11, 2022.
12. Egan L, Newling G, Uthurralt N, Riordan B, Day CA. (2022). Sydney's Inner-West micro-brewery tasting bars and development approvals, fact-based or not? An appraisal of documents submitted to council for development approval (Paper 22). **Drug and Alcohol Review** 41(S1): S58-59.
13. Clifford B, Shine P, Lo N, Stockwell T, Haber PS, Baldry E, Day CA, Dobbins T, Peacock A, Pauly B, Lintzeris N, Dolan K, Macklin B, Siefried KJ, Brett J, Dunlop AJ & Ezard N. (2022). The AusMAP study: A protocol for a randomised, controlled feasibility study of a managed alcohol program in Australia (Paper 265). **Drug and Alcohol Review** 41(S1): S44.
14. Hocknull K, Bartlett M, Jauncey M, Shand F, Geiger B, Colledge-Frisby S, Day CA, Roxburgh A. (2022). Managing suicidal crisis at the Sydney Medically Supervised Injecting Centre (Paper 259). **Drug and Alcohol Review** 41(S1): S44.
15. Kardell W, Day CA, Weltman M, Haber PS. (2022). Non-prescribed drug use among hospital inpatients (Paper 80). **Drug and Alcohol Review** 41(S1): S80.
16. Kim S, White B, Roberts J & Day CA. (2022). Prevalence of substance use among incarcerated pregnant women in New South Wales (Paper 143). **Drug and Alcohol Review** 41(S1): S81.

17. Moensted ML, Little S, & Day CA. (2022). Service providers' perspectives on youth-friendly drug and alcohol treatment: Preliminary findings (Paper 33). **Drug and Alcohol Review** 41(S1): S98.
18. Nithyanandam L & Day CA. (2022). Improving access to treatment and support for women with substance use disorder during the COVID-19 pandemic: The experience with telehealth from a women's only service (Paper 164). **Drug and Alcohol Review** 41(S1): S102-103.
19. Roxburgh A, Jauncey M, Day CA, Bartlett M, Cogger S, Livingston M, Dietze PM, Nielsen S, Latimer J & Clark N. (2022). The impact of COVID-19 on supervised injecting facilities in Australia (Paper 133). **Drug and Alcohol Review** 41(S1): S121-122.
20. Ryjenko O, Winter DT, Riordan BC, Day CA, Roxburgh A. (2022). Capturing key regulatory activities targeting pharmaceutical opioids in Australia: What has the last decade of policy looked like? (Paper 157). **Drug and Alcohol Review** 41(S1): S123.
21. Talwar A, Reid SE, Day CA. (2022). Healthcare workers as mandated reporters – What is the evidence? A narrative literature review (Paper 135). **Drug and Alcohol Review** 41(S1): S133-134.
22. Uthurralt N, Cao FM, Burns L, Reid SE, Day CA. (2022). Characteristics of clients entering women-only substance use treatment services in New South Wales, 2014–2018 (Paper 165). **Drug and Alcohol Review** 41(S1): S140.
23. Winter DT, Haber PS, Day CA. (2022). Alcohol and other drug healthcare staff perceptions regarding client reimbursement for participating in research (Paper 264). **Drug and Alcohol Review** 41(S1): S150.
24. Roberts DM. Trends in recreational drug use in Australia” and “What’s the appropriate management of toxicology-related rhabdomyolysis?”. 42nd Congress of the European Association of Poisons Centres and Clinical Toxicologists, Tallin Estonia, May 202 (invited lecture)

Presentations/media (n = 11)

1. Buckley NA. Toxic Syndromes from Psychiatric Medicines. **IMSanz Conference**. Sydney. Sept 2022 (Invited lecture)
2. Buckley NA. Cardiotoxicity workshop – QT prolongation. **TAPNA meeting**, Newcastle May 2022 (Invited lecture)
3. Lee K & Perry J. Re-thinking how we ask about drinking: the Grog Survey App. **APSAD 2022**, Darwin. 10 October 2022.
4. Doyle M & Roberts J. Alcohol and other drug use of Aboriginal people involved in the NSW criminal justice system. **Justice Health Conference, NSW 2022**. Sydney June 10, 2022.
5. K. Conigrave. **The James Rankin Oration. APSAD Conference**, Darwin, October 11, 2022
6. M. Doyle. Alcohol and other drug use of Aboriginal people involved in the NSW criminal justice system. **APSAD Conference**, Darwin, October 11, 2022.
7. TJ Weatherall, M. Doyle. L. Bullen, A. Stearne. Symposium: Pathways for Aboriginal and Torres Strait Islander peoples to lead the way in alcohol research, **APSAD Conference**, Darwin, October 11, 2022.
8. Conigrave K & Assan R. Supporting Aboriginal Community Controlled Health Services in screening and alcohol care: where to from here? **APSAD 2022** Darwin, October 11.
9. Lee K & Wilson S. Re-thinking how we ask about drinking: the Grog Survey App. Aboriginal Health Council of Western Australia. [online] 01 December 2022
10. Seth D. Invited speaker at the 16th Annual Charles Lieber Satellite Symposium: Alcohol, Opioids, Microbiome and Chronic Diseases, **45th Annual RSA Scientific Meeting**, Orlando Florida USA. 25-29 Jun 2022 (in person).
11. Seth D. Oral presentation, Gordon Research Conference - Alcohol-Induced End Organ Diseases: Developing Molecular Pathways into Therapeutic Opportunities for Alcohol-Associated Diseases.

'Clinical relevance of underlying genetics in patients with high alcohol use and cirrhosis: the GenomALC study'. **Ventura, CA, USA.** 24-29 Apr 2022 (in person).

Other achievements

1. A/Prof Carolyn Day (theme lead) was promoted to Professor.
2. A/Prof Kirsten Morley (theme lead) was promoted to Professor.
3. Dr. Devanshi Seth (theme lead) was promoted to Clinical Professor
4. Clinical Professor Devanshi Seth chaired Franklin Women Wiki-edit-a-thon for women in health & medical research, Apr 2022
5. Clinical Professor Devanshi Seth was an invited Panellist on UN- International Day of Women and Girls in Science 2022, The University of Canberra, 11 Feb 2022
6. Clinical Professor Devanshi Seth was an invited Panellist on International Day for women (IWD) 2022, Centenary Institute, 8 Mar 2022
7. Establishment of collaboration with and research partnership with NSW Alcohol and Drug Foundation (operating Kathleen York House), Network of *Alcohol* and other Drugs Agencies (*NADA*), Burnett Institute, Mission Australia, Uniting Australia (Medically Supervised Injecting Centre), Ambulance NSW -Carolyn Day
8. A/Prof Darren Roberts was a member, RACP COVID-19 Expert Reference Group
9. A/Prof Darren Roberts was a member, National Paediatric Medicines Forum, Australia
10. A/Prof Darren Roberts was a member, Drug and Therapeutics Committee, Sydney Children's Hospital Network, NSW
11. A/Prof Darren Roberts was a Co-chair, The Extracorporeal Treatments in Poisoning Workgroup (EXTRIP) Workgroup
12. A/Prof Darren Roberts was a member, Scientific Review Committee, American Association of Clinical Toxicology



Translational Research
Alcohol • Drugs • Toxicology

Edith Collins Centre
King George V Building
Missenden Road
Camperdown
NSW 2050